Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds
DUBLIN - Biopharmaceutical company Alkermes plc (NASDAQ:ALKS), which currently maintains a strong financial health score according to InvestingPro data, announced Friday the appointment of Joshua Reed as Chief Financial Officer, effective Monday, Sept. 15, 2025. The company demonstrates robust financial fundamentals with a healthy current ratio of 3.23 and minimal debt relative to its capital structure.
Reed, who will report to Chief Executive Officer Richard Pops and join the company’s management committee, brings over 30 years of financial leadership experience to the role. He most recently served as CFO of Omega Therapeutics and previously held the same position at Aldeyra Therapeutics.
His career includes more than a decade at Bristol Myers Squibb, where he rose to Vice President and Head of Finance Operations for the U.S. and Puerto Rico. Reed also worked at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank.
"I’m delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes’ strong financial foundation," Reed said in a statement.
Reed currently serves on the board of directors of Scholar Rock Holding Corporation, a publicly-traded biotechnology company. He holds a Bachelor of Science in Finance from Rutgers University and an MBA from the University of Michigan’s Ross School of Business.
Pops expressed confidence in the new appointment, citing Reed’s "wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry."
Alkermes, headquartered in Ireland with offices in Massachusetts and a manufacturing facility in Ohio, focuses on developing medicines in the field of neuroscience. The company’s portfolio includes treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.
The announcement was made in a press release issued by the company.
In other recent news, Alkermes reported impressive second-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.52, compared to the projected $0.36. Revenue also exceeded forecasts, reaching $390.7 million against the anticipated $347.16 million. Additionally, Alkermes announced positive Phase 2 results for its investigational narcolepsy treatment, alixorexton, which showed significant improvements in wakefulness, cognition, and fatigue in patients with narcolepsy type 1 (NT1). The six-week Vibrance-1 study demonstrated that alixorexton met its primary endpoint across all tested doses. Meanwhile, H.C. Wainwright reiterated its Neutral rating for Alkermes, maintaining a price target of $46.00 after the company presented detailed Phase 2 data from the Vibrance-1 study. Stifel maintained its Buy rating with a $42.00 price target, highlighting the compelling efficacy profile of alixorexton in narcolepsy type 1. These developments reflect recent progress and evaluations within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.